Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TGTX with free AI briefings, catalyst countdowns, and dilution alerts.

TGTX · TG Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$504.7M Cash on Hand
CF+ Cash Runway
27.7% Short Interest
$69.43 Analyst Target (7)
Follow TGTX by email Get an email when TGTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TGTX, unsubscribe in one click. Privacy

📣 What TGTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ublituximab Multiple Sclerosis Phase 4 · NCT07225361 Recruiting
Umbralisib (TGR-1202) Chronic Lymphocytic Leukemia Phase 2/3 · NCT03801525 Terminated
Bendamustine Diffuse Large B-Cell Lymphoma Phase 2/3 · NCT02793583 Terminated
Edralbrutinib (TG-1701) Non Hodgkin Lymphoma Phase 1 · NCT03671590 Terminated
Zeripatamig (TG-1801) CLL Phase 1 · NCT04806035 Terminated
Azercabtagene Zapreleucel B-cell Mediated Autoimmune Disorders Phase 1 · NCT06680037 Recruiting

Also used in these trials (approved or third-party drugs, not TGTX's own candidates): Ocrelizumab, Teriflunomide, Venetoclax, Obinutuzumab, Ibrutinib, Fingolimod Hydrochloride, Chlorambucil, Acalabrutinib, Rituximab, Pembrolizumab, Lenalidomide, Cosibelimab (TG-1501).

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TGTX holds $504.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TGTX files for a raise →

👥 Who Owns TGTX

Insiders 7.6% Institutions (577 holders) 78.8% Public and other holders 13.6%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 21,190,534 14.02% 2026-09-30
Michael S Weiss
CEO, Director
Insider 9,778,086 6.47% 2026-01-08
State Street Corporation Institution (13F) 8,488,874 5.62% 2026-09-30
Vanguard Portfolio Management Institution (13G, 5%+) 8,400,210 5.56% 2026-03-31
Vanguard Capital Management LLC Institution (13F) 6,256,425 4.14% 2026-09-30
Geode Capital Management, LLC Institution (13F) 3,703,676 2.45% 2026-09-30
Two Sigma Investments, LP Institution (13F) 3,370,273 2.23% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 3,279,204 2.17% 2026-09-30
Congress Asset Management Co Institution (13F) 2,606,516 1.72% 2026-09-30
Soleus Capital Management, L.P. Institution (13F) 2,556,168 1.69% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 2,500,759 1.65% 2026-09-30
Sean A Power
CFO
Insider 798,111 0.53% 2026-01-08

Share count 151,147,827 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-10
filed 2026-09-14
Charney Laurence N
Sale (S) 5,000 $54.96 168,640
2026-08-07
filed 2026-08-07
Charney Laurence N
Gift (G) 450 – 173,640
2026-08-07
filed 2026-08-07
Charney Laurence N
Gift (G) 500 – 174,090
2026-08-06
filed 2026-08-07
Charney Laurence N
Gift (G) 5,100 – 174,590
2026-06-11
filed 2026-06-15
Lonial Sagar
Option award (A) 8,325 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full TGTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TGTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.